Pfizer Stock: Company Sells Entire Haleon Stake

Pharmaceutical giant Pfizer has divested its complete shareholding in consumer health company Haleon for approximately £2.5 billion ($3.24 billion). The transaction was executed at 385 pence per share, with institutional investors and Haleon itself purchasing the stake. As part of the deal, the Sensodyne toothpaste manufacturer agreed to repurchase 44 million of its own shares from Pfizer. The entire transaction represents about 7.3 percent of Haleon's issued share capital. Following Pfizer's exit, BlackRock Investment Management (UK) Ltd will become Haleon's largest shareholder with over 5 percent ownership. Haleon, known for pain relief brands Panadol and Advil, was originally formed through the 2019 merger of GSK and Pfizer's consumer health businesses before being spun off by the British pharmaceutical company in 2022. Several financial institutions facilitated the transaction, with BofA Securities, Citigroup Global Markets Limited, and Goldman Sachs International serving as global coordinators.

Recent Trading Performance

Pfizer shares have shown positive momentum in New York trading, posting a 1.1 percent gain to reach $26.33. The stock touched an intraday high of $26.34 after opening at $26.21. With the 52-week high standing at $31.54, market analysts see potential upside of nearly 20 percent from current levels. Experts have set a median price target of $30.20 per share. Looking ahead, analysts forecast earnings of $2.96 per share for fiscal year 2025. In its most recent quarterly results, Pfizer reported impressive year-over-year revenue growth of 24.66 percent, with sales climbing to $17.76 billion. The company is expected to announce its Q1 2025 financial results on May 6, 2025.

Ad

Fresh Pfizer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Source StockWorld